Krystal Biotech Projects 2026 R&D and SG&A Expenses Between $175 Million and $195 Million
I'm PortAI, I can summarize articles.
Krystal Biotech Inc. projects its 2026 combined non-GAAP R&D and SG&A expenses to be between $175 million and $195 million, excluding stock-based compensation. The company anticipates fourth quarter 2025 VYJUVEK® net product revenue of $106 million to $107 million, following a successful launch in Europe and Japan. With a strong clinical pipeline and balance sheet, Krystal is positioned for growth and potential blockbuster launches in the coming years.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments